0001209191-23-052944.txt : 20231017 0001209191-23-052944.hdr.sgml : 20231017 20231017160528 ACCESSION NUMBER: 0001209191-23-052944 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20231017 DATE AS OF CHANGE: 20231017 EFFECTIVENESS DATE: 20231017 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Virax Biolabs Group Ltd CENTRAL INDEX KEY: 0001885827 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-495026 FILM NUMBER: 231329652 BUSINESS ADDRESS: STREET 1: 30 BROADWICK STREET CITY: LONDON STATE: X0 ZIP: W1F 8LX BUSINESS PHONE: 44 020 7788 7414 MAIL ADDRESS: STREET 1: 30 BROADWICK STREET CITY: LONDON STATE: X0 ZIP: W1F 8LX FORMER COMPANY: FORMER CONFORMED NAME: Virax Biolabs (Cayman) Ltd DATE OF NAME CHANGE: 20210930 D 1 primary_doc.xml X0708 D LIVE 0001885827 Virax Biolabs Group Ltd 20 North Audley Street London X0 UNITED KINGDOM W1K 6LX 44 020 7788 7414 CAYMAN ISLANDS None Virax Biolabs (Cayman) Ltd Corporation true 2021 James Alexander Cunliffe Foster 20 North Audley Street London X0 UNITED KINGDOM W1K 6LX Executive Officer Director Mark Ternouth 20 North Audley Street London X0 UNITED KINGDOM W1K 6LX Executive Officer Director Nigel McCracken 20 North Audley Street London X0 UNITED KINGDOM W1K 6LX Executive Officer Evan Norton 20 North Audley Street London X0 UNITED KINGDOM W1K 6LX Director Yair Erez 20 North Audley Street London X0 UNITED KINGDOM W1K 6LX Director Nelson Maurice Haight 20 North Audley Street London X0 UNITED KINGDOM 672 W1K Director Jason Davis 20 North Audley Street London X0 UNITED KINGDOM 672 W1K Executive Officer Biotechnology $1 - $1,000,000 06b false 2023-10-12 false true true true false 0 H.C. Wainwright & Co., LLC 375 None None 430 PARK AVENUE 3RD FLOOR NEW YORK NY NEW YORK 10022 NY NEW YORK 2150000 2150000 0 The offering relates to the sale of unregistered warrants to purchase ordinary shares which are exercisable immediately after issuance. The above offering amount does not include the proceeds to be received by the Company upon exercise of such warrants. false 1 150764 0 The placement agent is also entitled to 1.0% management fee ($21,537.68), non-accountable expenses in the amount of $85,000, clearing fee of $15,950, and warrants to purchase up to 513,850 ordinary shares. 2150000 true Issuer expects to use proceeds from the offering for research and development activities and other working capital which includes payment of salaries to executive officers. false Virax Biolabs Group Ltd /s/ Jason Davis Jason Davis Chief Financial Officer 2023-10-17